Skip to main content
Clinical Trials/NCT06101940
NCT06101940
Enrolling By Invitation
Not Applicable

A Multicenter Phenotype-Genotype Analysis of Type 1 Myotonic Dystrophy 1 Patients in China

Huashan Hospital1 site in 1 country500 target enrollmentAugust 1, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Huashan Hospital
Enrollment
500
Locations
1
Primary Endpoint
Changes in 10 Metre Walk Test (10MWT)
Status
Enrolling By Invitation
Last Updated
7 months ago

Overview

Brief Summary

Myotonic dystrophy 1 (DM1) is an autosomal, dominantly inherited neuromuscular disorder characterized by skeletal muscle weakness, myotonia, cardiac conduction abnormalities, cataracts, and other abnormalities. This disease results from an expansion of a cytosine-thymine-guanine (CTG) trinucleotide repeat in the 3'-untranslated region of the dystrophia myotonica protein kinase (DMPK) gene on chromosome 19. Currently, there is limited phenotype and genotype data available for DM1 patients with Chinese Han ethnicity. Therefore, this study aims to fill this gap and provide complementary data.

Detailed Description

This multicenter, prospective, observational study investigates the diagnosis and progression of Myotonic Dystrophy Type 1 (DM1) in Chinese patients through comprehensive data collection. The research protocol includes clinical assessments (strength evaluations, cognitive testing), diagnostic studies (genetic analysis, electromyography), imaging modalities (MRI, echocardiography, electrocardiography), functional evaluations (pulmonary function tests, posture and movement video analysis), and biological sampling (blood and muscle specimens). This integrated approach enables systematic characterization of DM1 manifestations across multiple organ systems, facilitating better understanding of disease progression patterns and potential biomarker identification in the Chinese population.

Registry
clinicaltrials.gov
Start Date
August 1, 2021
End Date
December 30, 2032
Last Updated
7 months ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Chongbo Zhao

Professor

Huashan Hospital

Eligibility Criteria

Inclusion Criteria

  • Age between 18-80 years
  • With enough cognitivie ability to understand the content and sign the informed consent form
  • With CTG repeats \>50 in DMPK gene, revealed by PCR test

Exclusion Criteria

  • Patients with severe mental illness, or severe anxiety and depression
  • With comorbidities such as traumatic brain injury and cranial tumors
  • A history of alcoholism, psychotropic substance abuse, etc.
  • Patients with severe medical conditions and unstable vital signs that cannot tolerate the tests.
  • Female in pregnancy

Outcomes

Primary Outcomes

Changes in 10 Metre Walk Test (10MWT)

Time Frame: Baseline, Year 3, Year 5

The 10 Metre Walk Test is a performance measure used to assess walking speed in meters per second over a short distance. It can be employed to determine functional mobility, gait, and vestibular function

Secondary Outcomes

  • Changes in ESS scale(Baseline, Year 3, Year 5)
  • Changes in FSS scale(Baseline, Year 3, Year 5)
  • Changes in Video Hand Opening Time (vHOT)(Baseline, Year 1, Year 3, Year 5)

Study Sites (1)

Loading locations...

Similar Trials